Efficacy, safety, and current applications of brimonidine.
The use of brimonidine to lower intraocular pressure has been the subject of considerable investigation. Variations of the initially approved drug including agents of a lower concentration (Alphagan P 0.15 and 0.1%, Allergan, Inc., Irvine, CA, USA) and a fixed-combination mating brimonidine with timolol (Combigan, Allergan) evolved the marketing and application of this therapy. We review available evidence regarding the efficacy and side effect profile of brimonidine as well as its role in glaucoma management. Brimonidine is an important component of topical glaucoma treatment that is most limited by local ocular intolerance.